79,661 Edwards Lifesciences Corporation $EW Shares Acquired by TrinityBridge Ltd

TrinityBridge Ltd grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 26,553.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,961 shares of the medical research company’s stock after purchasing an additional 79,661 shares during the quarter. TrinityBridge Ltd’s holdings in Edwards Lifesciences were worth $6,904,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Integrity Alliance LLC. grew its stake in Edwards Lifesciences by 27.5% in the 3rd quarter. Integrity Alliance LLC. now owns 4,038 shares of the medical research company’s stock valued at $349,000 after buying an additional 870 shares during the last quarter. Eads & Heald Wealth Management raised its holdings in Edwards Lifesciences by 1.5% in the 3rd quarter. Eads & Heald Wealth Management now owns 14,001 shares of the medical research company’s stock valued at $1,209,000 after acquiring an additional 212 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC lifted its position in Edwards Lifesciences by 6.8% during the third quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 22,632 shares of the medical research company’s stock worth $1,954,000 after acquiring an additional 1,440 shares during the last quarter. Next Level Wealth Planning LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $52,000. Finally, Signature Equity Partners LLC lifted its position in Edwards Lifesciences by 163.5% during the third quarter. Signature Equity Partners LLC now owns 440 shares of the medical research company’s stock worth $38,000 after acquiring an additional 273 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $95.32 on Wednesday. The business’s 50 day simple moving average is $88.31 and its 200 day simple moving average is $85.53. Edwards Lifesciences Corporation has a one year low of $74.66 and a one year high of $96.29. The stock has a market capitalization of $54.88 billion, a PE ratio of 54.78, a PEG ratio of 2.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Wall Street Analysts Forecast Growth

EW has been the topic of several research reports. Deutsche Bank Aktiengesellschaft set a $104.00 target price on Edwards Lifesciences in a research report on Tuesday, October 27th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, October 27th. Raymond James Financial boosted their price target on Edwards Lifesciences from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Citigroup restated a “buy” rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research note on Monday, October 5th. Finally, Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.88.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: In the PROGRESS trial, TAVR outperformed clinical surveillance on a two-year composite of death or heart-failure events among moderate aortic stenosis patients with at-risk features. The result could support earlier use of TAVR in selected patients. PROGRESS trial results
• Positive Sentiment: The CLASP II TR trial found Edwards’ PASCAL system superior to medical therapy alone at six months, with reduced tricuspid regurgitation and improved health status sustained through one year. This strengthens the clinical case for the company’s tricuspid-repair offering. CLASP II TR trial results
• Positive Sentiment: Bank of America’s analyst view was that PROGRESS supports expanding TAVR to selected moderate aortic stenosis patients, suggesting a potential new use for the procedure. Bank of America analyst view
• Negative Sentiment: RBC said the PROGRESS data are unlikely to meaningfully expand the overall TAVR market, a caveat to expectations that the trial will translate into broad commercial growth. RBC assessment of PROGRESS

Insiders Place Their Bets

In other news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.